Margaret C Fang1, Alan S Go, Yuchiao Chang, Leila H Borowsky, Niela K Pomernacki, Natalia Udaltsova, Daniel E Singer. 1. From the Departments of Medicine (M.C.F., A.S.G.) and Epidemiology & Biostatistics (A.S.G.), University of California, San Francisco; Division of Research (A.S.G., N.K.P., N.U.), Kaiser Permanente of Northern California, Oakland; and Clinical Epidemiology Unit (Y.C., L.H.B., D.E.S.), General Medicine Division, Massachusetts General Hospital, Boston.
Abstract
OBJECTIVES: While the short-term impact of atrial fibrillation-related stroke has been well studied, surprisingly little is known about its long-term effect on survival. METHODS: We followed 13,559 patients with atrial fibrillation for a median of 6 years, identifying ischemic strokes through computerized databases and validating 1,025 events. Stroke severity was determined from hospital records. We compared survival of stroke patients with comparator nonstroke patients (matched for age, sex, race, comorbid conditions, and time of entry into the cohort) using proportional hazard models controlling for warfarin use and compared survival by degree of discharge deficit. RESULTS: Median survival after stroke was 1.8 years compared with 5.7 years for matched nonstroke comparators (hazard ratio [HR] 2.8, 95% confidence interval [CI] 2.5-3.2). This increased risk of all-cause death persisted even after restricting the analysis to the 576 stroke patients who survived 6 months after the initial stroke event (HR 2.0, 95% CI 1.7-2.5, adjusting for warfarin use). Risk of death was strongly associated with stroke severity: HR 2.9 (95% CI 2.3-3.5) for strokes resulting in major deficits and HR 8.3 (95% CI 5.2-13.2) for strokes resulting in severe deficits compared with matched comparators without stroke. CONCLUSIONS: Ischemic stroke approximately triples the mortality rate in patients with atrial fibrillation. This effect persists well beyond the immediate period poststroke and is strongly associated with disability after stroke. Stroke prevention by anticoagulation has even greater beneficial effects on survival than usually considered when focusing solely on 30-day mortality rates.
OBJECTIVES: While the short-term impact of atrial fibrillation-related stroke has been well studied, surprisingly little is known about its long-term effect on survival. METHODS: We followed 13,559 patients with atrial fibrillation for a median of 6 years, identifying ischemic strokes through computerized databases and validating 1,025 events. Stroke severity was determined from hospital records. We compared survival of strokepatients with comparator nonstroke patients (matched for age, sex, race, comorbid conditions, and time of entry into the cohort) using proportional hazard models controlling for warfarin use and compared survival by degree of discharge deficit. RESULTS: Median survival after stroke was 1.8 years compared with 5.7 years for matched nonstroke comparators (hazard ratio [HR] 2.8, 95% confidence interval [CI] 2.5-3.2). This increased risk of all-cause death persisted even after restricting the analysis to the 576 strokepatients who survived 6 months after the initial stroke event (HR 2.0, 95% CI 1.7-2.5, adjusting for warfarin use). Risk of death was strongly associated with stroke severity: HR 2.9 (95% CI 2.3-3.5) for strokes resulting in major deficits and HR 8.3 (95% CI 5.2-13.2) for strokes resulting in severe deficits compared with matched comparators without stroke. CONCLUSIONS:Ischemic stroke approximately triples the mortality rate in patients with atrial fibrillation. This effect persists well beyond the immediate period poststroke and is strongly associated with disability after stroke. Stroke prevention by anticoagulation has even greater beneficial effects on survival than usually considered when focusing solely on 30-day mortality rates.
Authors: M Lamassa; A Di Carlo; G Pracucci; A M Basile; G Trefoloni; P Vanni; S Spolveri; M C Baruffi; G Landini; A Ghetti; C D Wolfe; D Inzitari Journal: Stroke Date: 2001-02 Impact factor: 7.914
Authors: Steven Vernino; Robert D Brown; James J Sejvar; JoRean D Sicks; George W Petty; W Michael O'Fallon Journal: Stroke Date: 2003-07-10 Impact factor: 7.914
Authors: Elaine M Hylek; Alan S Go; Yuchiao Chang; Nancy G Jensvold; Lori E Henault; Joe V Selby; Daniel E Singer Journal: N Engl J Med Date: 2003-09-11 Impact factor: 91.245
Authors: Alan S Go; Elaine M Hylek; Yuchiao Chang; Kathleen A Phillips; Lori E Henault; Angela M Capra; Nancy G Jensvold; Joe V Selby; Daniel E Singer Journal: JAMA Date: 2003-11-26 Impact factor: 56.272
Authors: Emer R McGrath; Alan S Go; Yuchiao Chang; Leila H Borowsky; Margaret C Fang; Kristi Reynolds; Daniel E Singer Journal: J Am Geriatr Soc Date: 2016-12-30 Impact factor: 5.562
Authors: Jeffrey M Ashburner; Alan S Go; Yuchiao Chang; Margaret C Fang; Lisa Fredman; Katie M Applebaum; Daniel E Singer Journal: J Am Coll Cardiol Date: 2016-01-26 Impact factor: 24.094
Authors: S Timsit; P Bailly; E Nowak; F M Merrien; D Hervé; I Viakhireva-Dovganyuk; A Jourdain; E Thomas; P Goas; F Rouhart Journal: Eur Stroke J Date: 2016-09-10
Authors: Wesley T O'Neal; Jimmy T Efird; Saman Nazarian; Alvaro Alonso; Susan R Heckbert; Elsayed Z Soliman Journal: J Am Heart Assoc Date: 2014-11-17 Impact factor: 5.501
Authors: Antonio Arauz; Francisco Ruiz-Navarro; Miguel A Barboza; Angelica Ruiz; Jonathan Colin; Marisela Reyes; Humberto Silos; Carlos Cantu-Brito; Luis Murillo-Bonilla; Fernando Barinagarrementeria Journal: J Vasc Interv Neurol Date: 2017-12